Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4(+) T Cells of Patients with Relapsing-Remitting Multiple Sclerosis

Por Meira, Maria, Sievers, Claudia, Hoffmann, Francine, Rasenack, Maria, Kuhle, Jens, Derfuss, Tobias, Kappos, Ludwig, Lindberg, Raija L. P.
Publicado em 2014

Natalizumab-induced POU2AF1/Spi-B upregulation: A possible route for PML development

Por Meira, Maria, Sievers, Claudia, Hoffmann, Francine, Haghikia, Aiden, Rasenack, Maria, Décard, Bernhard F., Kuhle, Jens, Derfuss, Tobias, Kappos, Ludwig, Lindberg, Raija L.P.
Publicado no Neurol Neuroimmunol Neuroinflamm (2016)